Rybelsus was available in 3 mg, 7 mg, and 14 mg tablets. Treatment typically started at 3 mg once daily for the first month, this starting dose was for treatment initiation and was not intended to be effective for blood sugar control on its own. After one month, the dose was commonly increased to 7 mg, and if additional blood sugar control was needed, to a maximum of 14 mg once daily.

A Real, Important Safety Note on the Transition: the new Ozempic tablet formulation uses different, lower mg doses that are bioequivalent, not mg-for-mg identical, to the old Rybelsus doses: Ozempic 1.5mg is bioequivalent to Rybelsus 3mg, Ozempic 4mg to Rybelsus 7mg, and Ozempic 9mg to Rybelsus 14mg. A real, documented UK drug safety alert (December 2025) specifically warned of medication-error risk during this transition, patients or providers mistakenly taking more than one tablet of the new formulation to try to "match" old dose numbers can result in real overdose risk. If you're transitioning between these formulations, follow your provider's specific guidance rather than converting doses yourself.

This dosing schedule is presented for reference only, since Rybelsus is no longer being newly prescribed in the US. Patients transitioning to the new Ozempic tablet follow a separate dosing schedule set by their provider.